CL2007003483A1 - Compuestos derivados de indol-2-il-carbonil-espiro-piperidina, antagonistas del receptor de la v1a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de hipertension, dismeno - Google Patents

Compuestos derivados de indol-2-il-carbonil-espiro-piperidina, antagonistas del receptor de la v1a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de hipertension, dismeno

Info

Publication number: CL2007003483A1
Authority: CL; Chile
Prior art keywords: compound; desmeno; piperidina; espiro; carbonil
Prior art date: 2006-12-07

Application number

CL200703483A

Other languages

English (en)

Inventor

Bissantz Christophe G Caterina

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-07

Filing date

2007-12-04

Publication date

2008-07-04

2007-12-04 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-07-04 Publication of CL2007003483A1 publication Critical patent/CL2007003483A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

CL200703483A 2006-12-07 2007-12-04 Compuestos derivados de indol-2-il-carbonil-espiro-piperidina, antagonistas del receptor de la v1a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de hipertension, dismeno CL2007003483A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP06125645		2006-12-07

Publications (1)

Publication Number	Publication Date
CL2007003483A1 true CL2007003483A1 (es)	2008-07-04

Family

ID=39201604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200703483A CL2007003483A1 (es)	2006-12-07	2007-12-04	Compuestos derivados de indol-2-il-carbonil-espiro-piperidina, antagonistas del receptor de la v1a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de hipertension, dismeno

Country Status (21)

Country	Link
US (2)	US8022213B2 (es)
EP (1)	EP2099799B1 (es)
JP (1)	JP2010511654A (es)
KR (1)	KR101111022B1 (es)
CN (1)	CN101541797A (es)
AR (1)	AR064136A1 (es)
AT (1)	ATE469899T1 (es)
AU (1)	AU2007329066B2 (es)
BR (1)	BRPI0720246A2 (es)
CA (1)	CA2670671A1 (es)
CL (1)	CL2007003483A1 (es)
DE (1)	DE602007006989D1 (es)
ES (1)	ES2343286T3 (es)
IL (1)	IL198549A0 (es)
MX (1)	MX2009005507A (es)
NO (1)	NO20091766L (es)
PE (1)	PE20081489A1 (es)
RU (1)	RU2009119393A (es)
TW (1)	TW200843758A (es)
WO (1)	WO2008068159A1 (es)
ZA (1)	ZA200903175B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE488519T1 (de) *	2005-09-28	2010-12-15	Hoffmann La Roche	Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
AU2010209825A1 (en) *	2009-01-30	2011-08-11	F. Hoffmann-La Roche Ag	Piperidine derivatives as NK3 receptor antagonists
US8324250B2 (en) *	2009-03-19	2012-12-04	Hoffmann-La Roche Inc.	Piperidine derivatives as NK3 receptor antagonists
PL3083633T3 (pl)	2013-12-19	2018-04-30	F.Hoffmann-La Roche Ag	Spirooksazolony
CN111212842B (zh) *	2017-09-05	2022-10-25	布莱克索恩治疗公司	血管加压素受体拮抗剂以及与其相关的产品和方法
WO2020048826A1 (en)	2018-09-03	2020-03-12	Bayer Aktiengesellschaft	5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
TW202024083A (zh)	2018-09-03	2020-07-01	德商拜耳廠股份有限公司	3,9-二氮雜螺[5.5]十一烷化合物
WO2020048830A1 (en)	2018-09-03	2020-03-12	Bayer Aktiengesellschaft	5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048831A1 (en)	2018-09-03	2020-03-12	Bayer Aktiengesellschaft	5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en)	2018-09-03	2020-03-12	Bayer Pharma Aktiengesellschaft	5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CO5150201A1 (es)	1998-09-07	2002-04-29	Hoffmann La Roche	Derivados de piperidina
CZ301464B6 (cs)	2000-05-12	2010-03-10	Solvay Pharmaceuticals B. V.	Piperazinové a piperidinové slouceniny, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují
JP2006505570A (ja)	2002-10-17	2006-02-16	アムジエン・インコーポレーテツド	ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
CA2551038C (en) *	2003-12-22	2010-04-27	Pfizer Inc.	Triazole derivatives as vasopressin antagonists
US7351706B2 (en) *	2006-01-05	2008-04-01	Hoffmann-La Roche Inc.	Indol-3-yl-carbonyl-spiro-piperidine derivatives

2007
- 2007-11-27 AU AU2007329066A patent/AU2007329066B2/en not_active Ceased
- 2007-11-27 JP JP2009539698A patent/JP2010511654A/ja not_active Ceased
- 2007-11-27 DE DE602007006989T patent/DE602007006989D1/de active Active
- 2007-11-27 AT AT07847384T patent/ATE469899T1/de active
- 2007-11-27 CN CNA2007800432751A patent/CN101541797A/zh active Pending
- 2007-11-27 MX MX2009005507A patent/MX2009005507A/es active IP Right Grant
- 2007-11-27 BR BRPI0720246-6A patent/BRPI0720246A2/pt not_active IP Right Cessation
- 2007-11-27 CA CA002670671A patent/CA2670671A1/en not_active Abandoned
- 2007-11-27 WO PCT/EP2007/062857 patent/WO2008068159A1/en not_active Ceased
- 2007-11-27 KR KR1020097011663A patent/KR101111022B1/ko not_active Expired - Fee Related
- 2007-11-27 ES ES07847384T patent/ES2343286T3/es active Active
- 2007-11-27 RU RU2009119393/04A patent/RU2009119393A/ru not_active Application Discontinuation
- 2007-11-27 EP EP07847384A patent/EP2099799B1/en not_active Not-in-force
- 2007-11-30 US US11/947,836 patent/US8022213B2/en not_active Expired - Fee Related
- 2007-11-30 US US11/947,822 patent/US7432259B2/en not_active Expired - Fee Related
- 2007-12-04 TW TW096146110A patent/TW200843758A/zh unknown
- 2007-12-04 CL CL200703483A patent/CL2007003483A1/es unknown
- 2007-12-05 AR ARP070105427A patent/AR064136A1/es unknown
- 2007-12-06 PE PE2007001737A patent/PE20081489A1/es not_active Application Discontinuation
2009
- 2009-05-04 IL IL198549A patent/IL198549A0/en unknown
- 2009-05-05 NO NO20091766A patent/NO20091766L/no not_active Application Discontinuation
- 2009-05-07 ZA ZA200903175A patent/ZA200903175B/xx unknown

Also Published As

Publication number	Publication date
US20080161298A1 (en)	2008-07-03
AR064136A1 (es)	2009-03-18
ATE469899T1 (de)	2010-06-15
US20080161299A1 (en)	2008-07-03
CA2670671A1 (en)	2008-06-12
DE602007006989D1 (en)	2010-07-15
NO20091766L (no)	2009-07-06
PE20081489A1 (es)	2008-10-30
US7432259B2 (en)	2008-10-07
MX2009005507A (es)	2009-06-03
BRPI0720246A2 (pt)	2013-12-31
WO2008068159A1 (en)	2008-06-12
ZA200903175B (en)	2010-03-31
KR101111022B1 (ko)	2012-03-14
ES2343286T3 (es)	2010-07-27
AU2007329066B2 (en)	2012-04-12
CN101541797A (zh)	2009-09-23
EP2099799B1 (en)	2010-06-02
RU2009119393A (ru)	2011-01-20
US8022213B2 (en)	2011-09-20
JP2010511654A (ja)	2010-04-15
EP2099799A1 (en)	2009-09-16
AU2007329066A1 (en)	2008-06-12
KR20090080112A (ko)	2009-07-23
IL198549A0 (en)	2010-02-17
TW200843758A (en)	2008-11-16

Similar Documents

Publication	Publication Date	Title
CL2007003483A1 (es)	2008-07-04	Compuestos derivados de indol-2-il-carbonil-espiro-piperidina, antagonistas del receptor de la v1a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de hipertension, dismeno
CL2007003266A1 (es)	2008-07-04	Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
CL2007003697A1 (es)	2008-07-04	Compuestos derivados de sulfonamida; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la hiperglucemia, diabetes, obesidad, hipertension, hiperlipidemia, sindrome metabol
CL2007001870A1 (es)	2008-06-13	Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
CL2009000171A1 (es)	2009-11-27	Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
CL2007002167A1 (es)	2009-01-23	Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
BRPI0605921A2 (pt)	2009-05-26	compostos orgánicos
CL2013001885A1 (es)	2014-03-28	Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
CL2004000449A1 (es)	2005-01-07	Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en
CL2007003299A1 (es)	2008-08-22	Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
DK2374797T3 (da)	2014-05-12	Benzazepinderivater til anvendelse som vasopressinantagonister
CL2007001992A1 (es)	2008-07-18	Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
CL2008000066A1 (es)	2008-08-01	Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
BRPI0908097A2 (pt)	2015-12-01	uso de pelo menos um composto, peptídeo, e, formulação farmacêutica.
CL2008000059A1 (es)	2008-07-18	Compuestos derivados de espiropiperidina-glicinamida; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hipertension, dismenorrea, fallo cardiaco cronico, ansiedad, t
CL2007003481A1 (es)	2008-07-04	Compuestos derivados de 2-aminoquinolina, antagonistas de los receptores 5-ht5a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la depresion, ansiedad, esquizofrenia, d
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
CL2007002611A1 (es)	2008-03-14	Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad.
BRPI0810019A2 (pt)	2014-10-14	Composto, composição farmacêutica, e, uso de um composto
BRPI0716698A2 (pt)	2014-02-25	Composto, composição farmacêutica e uso de um composto
CL2008003266A1 (es)	2009-10-16	Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
CL2008000303A1 (es)	2008-08-08	Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion.